Pressekonferenz morgen nach Börsenschluß!!!!!!!!!!!!!!!!!!!!!!!
After-hours PR: Conference call tomorrow. . .
(PR NEWSWIRE) Calypte Biomedical To Host Conference Call
Calypte Biomedical To Host Conference Call
CEO to Discuss The International AIDS Conference and
Recent Clinical Data Disclosed at Event
Conference Call Scheduled for Tomorrow, Thursday, July 22, 2004
at 11:00AM EDT. Dial-In Number is 1-800-915-4836. Simultaneous Webcast With
Moderator Activated Slide Presentation at
www.shareholder.com/calypte/medialist.cfm PLEASANTON, Calif., July 21 /PRNewswire-FirstCall/ -- Calypte Biomedical
Corporation (OTC Bulletin Board: CYPT), announced today that Dr. Richard
George, Calypte's President and Chief Executive Officer, will host a
conference call on Thursday morning at 11:00 am EDT to discuss the recently
concluded XV International AIDS Conference in Bangkok, Thailand, as well as
provide an in-depth discussion of the recently released data from the Thailand
field trials on the Company's HIV-1/2 rapid urine, oral fluid and blood tests.
Investors in the U.S. and Canada interested in participating in the
conference call may dial 800-915-4836 and reference the Calypte Biomedical
call. International investors may dial 973-317-5319.
A live webcast of the conference call accompanied by a moderator activated
slide presentation will be available at
www.shareholder.com/calypte/medialist.cfm . The webcast will be
available until August 5, 2004.
A replay of the call will be available through August 5, 2004 by calling
888-203-1112 in the U.S. and Canada and 719-457-0820 for international
listeners. The replay confirmation code is
693031.
The quarterly investors' call on the results of the second quarter ended
June 30, 2004 will be held as a separate call on August 12, 2004.
ABOUT CALYPTE BIOMEDICAL:
Calypte Biomedical Corporation, headquartered in Pleasanton, California,
is a public healthcare company dedicated to the development and
commercialization of in vitro diagnostic tests, primarily for the detection of
antibodies to Human Immunodeficiency Virus (HIV), and other sexually
transmitted and infectious diseases. Calypte's currently marketed laboratory-
based tests include an enzyme immunoassay (EIA) HIV-1 antibody screening test
and an HIV-1 antibody western blot supplemental test, the only two FDA-
approved HIV-1 antibody tests for use on urine samples, as well as an FDA-
approved serum HIV-1 antibody western blot supplemental test. Calypte is
actively engaged in developing new test products for the rapid detection of
HIV and other infectious diseases. Calypte believes that there is a
significant need for rapid detection of such diseases globally to control
their proliferation, particularly in lesser-developed countries, which lack
the medical infrastructure to support laboratory-based testing. Calypte
believes that testing for HIV and other infectious diseases may make important
contributions to public health.
CONTACT:
Dr. Richard George, President and CEO
Calypte Biomedical Corp.
925.730.7200
rgeorge@calypte.com
Tim Clemensen
Rubinstein Investor Relations
212.843.9337
tclemensen@rubensteinir.com
SOURCE Calypte Biomedical Corporation
-0- 07/21/2004
/CONTACT: Dr. Richard George, President and CEO of Calypte Biomedical
Corp., +1-925-730-7200, rgeorge@calypte.com; or Tim Clemensen, of
Rubinstein Investor Relations, +1-212-843-9337, tclemensen@rubensteinir.com
for Calypte Biomedical Corporation/
/Web site:
www.calypte.com www.shareholder.com/calypte/medialist.cfm /
(CYPT)
CO: Calypte Biomedical Corporation
ST: California, Thailand
IN: HEA MTC BIO OTC
SU: CCA TDS
*** end of story ***